2022
article
OpenAlex
Edvan de Queiroz Crusoé, Joanna Leal, Juliana Andrade Santos, Herbert Henrique de Melo Santos et autres
Background: The introduction of monoclonal antibodies (mAb) such as daratumumab created a new landscape for MM treatment. The four-drug combo has becoming one of the main induction treatment for TE NDMM patients (pts). We conducted a phase 2 study to assess the …
br
(code pays fourni par la source)
2021
conference-abstract
OpenAlex
Edvan de Queiroz Crusoé, Joanna Leal, Marco Aurélio Salvino, Larissa Ferreira Lucas et autres
Abstract Background: Newly drugs access for MM treatment still a challenge in some countries. One of the most available inductions for TE NDMM patients (pts) worldwide is cyclophosphamide (C), thalidomide (T) and dexamethasone (d)-(CTd). Dara the first anti- CD38, had been combined …
br
(code pays fourni par la source)
2021
conference-abstract
OpenAlex
Herbert Henrique de Melo Santos, Glaciano Ribeiro, Allan de souza Santos, Marcos Chaves et autres
Abstract Introduction- Next generation flow (NGF) is one of the approaches for testing multiple myeloma (MM) minimal residual disease (MRD) over conventional response assessments. Actually, bone marrow (BM) is the preference site of evaluation because of its sensitivity. Because of its invasively …
br
(code pays fourni par la source)
2020
article
OpenAlex
Allan de souza Santos, Herbert Henrique de Melo Santos, Marco Aurélio Salvino, Sarah Queiroz Silva et autres
Background: CD38-targeting antibody Daratumumab (Dara) has been demonstrating significant improvement in (MM) patient's survival. Cyclophosphamide (C), thalidomide (T) and dexamethasone (D) - (CTd) is one of the most used induction protocols worldwide and the MAX-Dara study was the first that combine Dara-CTd …
br
(code pays fourni par la source)
2020
article
OpenAlex
Edvan de Queiroz Crusoé, Marco Aurélio Salvino, Sarah Queiroz Silva, Herbert Henrique de Melo Santos et autres
Background: The inclusion of the CD38-targeting antibody daratumumab (Dara) increases the depth and duration of the response, as demonstrated by Dara-VTd and Dara-VRd protocols to treat NDMM - TE patients (pts). However, the access to new drugs is a challenge for some …
br
(code pays fourni par la source)